Amberwell, UAB - financials and debts

Company age: 14 y. 0 mo.

Update

Amberwell - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 0 0 0 7,828 69,354 28,170 77,603 90,810
Profit before tax - - - - - - - 3,633
Net profit 0 0 0 1,488 6,830 921 68 3,415
Equity 2,896 2,896 2,896 4,384 11,214 5,575 5,643 9,205
Liabilities 0 0 0 78 359 3,646 1,485 7,340
Non-current assets 0 0 0 0 0 667 1,784 947
Current assets 2,896 2,896 2,896 4,462 11,573 8,554 5,344 15,598
Total assets 2,896 2,896 2,896 4,462 11,573 9,221 7,128 16,545
Taxes paid
STI taxes - - - - - 4,880 5,476 4,739
Financial indicators
Revenue change y/y - - - - +786.0% -59.4% +175.5% +17.0%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 0.0% 0.0% 0.0% 33.3% 59.0% 10.0% 1.0% 20.6%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 0.0% 0.0% 0.0% 33.9% 60.9% 16.5% 1.2% 37.1%
Profit margin Net profit margin. Shows the overall profitability of the company. - - - 19.0% 9.8% 3.3% 0.1% 3.8%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - - - - - 4.0%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - 0.0 0.0 0.7 0.3 0.8
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - 7,828 69,354 28,170 77,603 90,810

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Amberwell - Social security debts

From To Debt, €
2026-07-19 2026-07-19 4.50
2026-07-16 2026-07-17 4.50
2026-06-16 2026-06-25 4.30
2025-01-22 2025-02-16 0.12
2024-10-16 2024-11-17 0.03
2024-09-17 2024-10-13 0.03
2024-01-23 2024-01-30 0.89
2024-01-16 2024-01-16 203.52
2023-12-18 2023-12-18 203.87
2023-11-16 2023-11-19 204.22
2023-10-25 2023-11-15 0.35
2023-10-17 2023-10-22 202.41
2023-09-18 2023-09-18 202.41
2023-08-17 2023-08-17 202.41
2023-05-16 2023-05-16 202.29
2022-12-19 2022-12-19 175.16
2022-12-16 2022-12-18 154.98
2022-10-18 2022-10-20 142.99

Amberwell - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Amberwell is: 10 €

From To Overdue, €
2026-09-01 2026-09-02 10.34
2026-08-27 2026-08-31 10.24
2026-08-25 2026-08-26 30.24
2026-08-20 2026-08-24 30.0
2026-07-30 2026-08-13 9.14

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Amberwell, UAB (code 302872865) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the latest financial year, the company generated revenue of €90.8K, up 17.0% year on year and 222.4% over two years. Net profit reached €3.4K, compared with €68 in 2024 and €921 in 2023, indicating a clear recovery after a very weak 2024 result. The 2025 profit margin was 3.8%, versus 0.1% in 2024 and 3.3% in 2023. Balance sheet size also expanded, with total assets rising to €16.5K from €7.1K in 2024, while equity increased to €9.2K and liabilities to €7.3K. The equity ratio stood at 55.6%, debt-to-equity at 0.80, and asset turnover at 5.49x. Return on equity was 37.1% and return on assets 20.6% in 2025. Revenue and profit per employee were €90.8K and €3.4K, respectively.